New Strategies to Block RIPK1/3/MLKL-Mediated Neurodegeneration

Case ID:

University of Arizona researchers have discovered several small molecules that represent a new class of RIPK1/3 targeting therapeutics that can potentially be used in the treatment of Alzheimer’s Disease. These molecules inhibit necroptosis, which is a cell death pathway related to neurodegenerative diseases. Necroptosis is form of cell death which is activated by inflammation.



Finding disease-modifying treatments for Alzheimer’s Disease (AD) and related dementias is critical. The prevalence of dementia is rising rapidly with over 50 million people afflicted world-wide and is anticipated to grow to 82 million by 2030. The accompanying global healthcare burden reached $1.1 trillion dollars in 2018 and is expected to reach $2 trillion by 2030.


The path to finding disease-modifying treatments for AD has been challenging, but also represents enormous opportunity for research and investment. Since 1998, there have been 100 attempts to develop an effective drug treatment; however, only four drugs, falling into two categories have been approved. A fifth drug, Tacrine, was discontinued because of serious adverse events and a sixth drug which is a combination of two approved drugs. These drugs treat AD symptoms. The pipeline through 2018 looked promising; however, several of pipeline drugs have failed during subsequent clinical trials. There are several drugs in various stages of development, only a couple are in late stage clinical trials. Recently, the National Institute of Health has been given a big increase in funding and new drug discovery work also funded through venture capital firms.



  • Treatment for Alzheimer’s Disease and related dementias



  • Represents a new class of RIPK1/3 targeting therapeutics for Alzheimer’s Disease
Patent Information:
Contact For More Information:
Mitch Graffeo
Sr. Licensing Manager - COM-T
The University of Arizona
Lead Inventor(s):
May Khanna
Jonathan Sanchez
Vijay Gokhale
Salvatore Oddo